WARNING
| USE IN PREGNANCY: When
used in pregnancy during the second and third trimesters,
ACE inhibitors can cause injury and even death to
the developing fetus. When pregnancy is detected,
ramipril should be discontinued as soon as possible.
(See WARNINGS, Fetal/neonatal morbidity and
mortality.) |
DESCRIPTION
Ramipril is a 2-aza-bicyclo [3.3.0]-octane-3-carboxylic
acid derivative. It is a white, crystalline substance
soluble in polar organic solvents and buffered aqueous
solutions. Ramipril melts between 105°C and 112°C.
The CAS Registry Number is 87333-19-5. Ramipril's chemical
name is (2S,3aS,6aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic
acid, 1-ethyl ester.
Its empiric formula is C23H32N2O5, and its molecular
weight is 416.5.
Ramiprilat, the diacid metabolite of ramipril, is a non-sulfhydryl
angiotensin converting enzyme inhibitor. Ramipril is converted
to ramiprilat by hepatic cleavage of the ester group.
Altace (ramipril) is supplied as hard shell capsules
for oral administration containing 1.25 mg, 2.5 mg, 5
mg, and 10 mg of ramipril. The inactive ingredients present
are pregelatinized starch NF, gelatin, and titanium dioxide.
The 1.25 mg capsule shell contains yellow iron oxide,
the 2.5 mg capsule shell contains D&C yellow #10 and
FD&C red #40, the 5 mg capsule shell contains FD&C
blue #1 and FD&C red #40, and the 10 mg capsule shell
contains FD&C blue #1.
| 
